Cargando…
Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
The vaso-active drug hydralazine causes a considerable increase in the cytotoxic effect of melphalan towards the KHT tumour in mice. The enhancement in response, measured as the concentration of melphalan required to achieve a given tumour response, is 3.0 and 2.35 when determined using the regrowth...
Autores principales: | Stratford, I. J., Adams, G. E., Godden, J., Nolan, J., Howells, N., Timpson, N. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246762/ https://www.ncbi.nlm.nih.gov/pubmed/3166900 |
Ejemplares similares
-
Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
por: Siemann, D. W.
Publicado: (1990) -
Enhancing effect of pre-treatment of cells with misonidazole in hypoxia on their response to melphalan in air.
por: Smith, E., et al.
Publicado: (1982) -
The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
por: Hinchliffe, M., et al.
Publicado: (1983) -
Potentiation of melphalan activity against a murine tumour by nitroimidazole compounds.
por: Sheldon, P. W., et al.
Publicado: (1982) -
Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)